EXHIBIT B
New Molecular Entities Approved 2012 to 2015 Without Results Reported

1. “CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC).” See A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator’s Choice), ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/results/NCT02187302 (primary completion date July 2016) (last updated April 20, 2017).


6. “A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)” See, A Phase 3, Randomized, Double-


